Understand Parkinson's disease treatment options: A clinical overview

How Parkinson’s treatment is planned

There is currently no cure for Parkinson’s disease, but treatment can manage symptoms, maintain function, and improve quality of life. Care is generally tailored to symptoms, age, lifestyle, disease stage, general health, and personal treatment goals rather than following one fixed protocol. Regular neurological review is important because medication effects, motor symptoms, non-motor symptoms, and treatment risks can change over time. 1

A multidisciplinary team may include a movement disorder specialist, physical therapist, occupational therapist, speech-language pathologist, and mental health professional. This broader model matters because Parkinson’s disease can affect movement as well as mood, sleep, cognition, digestion, blood pressure, speech, and swallowing. Treatment therefore involves more than controlling tremor or slowness, with separate assessment often needed for non-motor problems. 2

Medication options for movement symptoms

Levodopa combined with carbidopa is generally the most effective medication for improving motor symptoms such as bradykinesia, rigidity, and tremor. The American Academy of Neurology guidance cited by Parkinsons.org states that levodopa provides greater benefit than dopamine agonists and MAO-B inhibitors for early motor symptoms, and it is generally preferred for many patients, particularly those older than 60. 3

Other medicines may be selected when symptoms are mild, when levodopa needs supplementation, or when side-effect risks influence the decision. Options include dopamine agonists, MAO-B inhibitors such as rasagiline, selegiline, or safinamide, COMT inhibitors such as entacapone or opicapone, amantadine, and adenosine A2A antagonists. Anticholinergic drugs may have a limited role, but age, cognition, hallucination risk, and other health factors must be considered. 4

Managing wearing-off and dyskinesia

As Parkinson’s disease progresses, a dose of levodopa may not last as long, producing “wearing-off” periods in which slowness or stiffness returns before the next dose. Clinicians may adjust dose timing or add a COMT inhibitor, MAO-B inhibitor, or adenosine A2A antagonist to extend levodopa’s effect. Extended-release levodopa, apomorphine rescue treatment, and infusion therapies may also be considered in advanced disease. 3

Dyskinesia refers to involuntary movements that can occur after prolonged levodopa treatment or during medication-related fluctuations. Dose adjustments may help, while amantadine extended-release is identified by Parkinsons.org as the only FDA-approved treatment specifically for levodopa-induced dyskinesia. Medication changes require monitoring because attempts to improve one period of the day can worsen another symptom or produce adverse effects. 3

Rehabilitation, exercise, and daily function

Physical therapy can address gait, balance, strength, flexibility, transfers, and fall prevention. Occupational therapy focuses on daily activities, home safety, energy conservation, and practical adaptations. Speech therapy can address reduced vocal volume, communication, and swallowing, with programs such as LSVT LOUD included among rehabilitation approaches described for Parkinson’s disease. 1

Exercise is a central component of supportive care, although it does not replace medication or specialist assessment. Programs may include aerobic activity, strength work, balance training, stretching, and task-specific practice selected according to ability and safety. Research summarized in the supplied Parkinsons.org material indicates that exercise may slow disease progression, while established clinical sources describe exercise and rehabilitation as tools for preserving mobility and independence. 5

Advanced and surgical treatments

Deep brain stimulation, or DBS, uses an implanted device to send electrical signals to specific brain regions. It may reduce medication-responsive motor symptoms and medication-related fluctuations in carefully selected people whose symptoms remain inadequately controlled. DBS does not cure Parkinson’s disease and does not reliably treat every symptom, especially many non-motor problems. Assessment commonly considers cognition, psychiatric health, overall medical condition, symptom responsiveness, and surgical suitability. 6

Other advanced approaches include levodopa delivered through an intestinal gel, subcutaneous medication infusion, lesioning procedures, and MRI-guided focused ultrasound. Focused ultrasound is a noninvasive lesioning technique for selected medication-refractory tremor or other specific motor symptoms, but it is not appropriate for everyone and does not address all Parkinson’s symptoms. These interventions involve eligibility reviews, procedural risks, follow-up, and continuing management rather than a permanent cure. 7

Non-motor symptoms and treatment realities

Depression, anxiety, constipation, sleep disturbance, pain, orthostatic hypotension, cognitive changes, and autonomic dysfunction can substantially affect wellbeing and independence. Each problem may require a separate evaluation involving medication, behavioral strategies, physical measures, or referral to another specialist. A treatment plan focused only on tremor and slowness can therefore miss symptoms that contribute significantly to disability. 2

Every option has potential limitations. Dopamine agonists can be unsuitable for people at risk of impulse-control problems or cognitive impairment, while medication combinations can create side effects and complicated schedules. Surgery and device-assisted treatment require careful selection, procedural oversight, equipment management, and ongoing follow-up. Treatment decisions should be reviewed with a qualified neurologist, particularly when hallucinations, sudden confusion, falls, swallowing difficulty, severe sleepiness, or major medication fluctuations occur. 8

How options may evolve over time

Early treatment may involve observation and exercise when symptoms have minimal functional impact, an MAO-B inhibitor for selected mild cases, or levodopa when symptoms interfere with quality of life. When daily activities become more difficult, levodopa and carbidopa are commonly central to treatment. Later stages may require combination therapy, adjustment of timing, treatment for dyskinesia, or consideration of infusion or surgical options. 3

The practical objective is not simply to add more treatment, but to balance mobility, independence, symptom control, safety, and quality of life. Response varies between individuals, and the most suitable option can change with age, cognition, disease stage, home circumstances, and treatment complications. Ongoing review with a neurologist or movement disorder specialist helps determine whether medication, rehabilitation, non-motor symptom care, or advanced therapy should be modified. 1

Sources

1. Parkinsons.org, “Parkinson’s Disease Treatments”
2. Cold Spring Harbor Perspectives in Medicine, “Clinical Management of Parkinson’s Disease: Features, Diagnosis, and Principles of Treatment”
3. Parkinsons.org, “Parkinson’s Disease Medications”
4. Merck Manual Professional Edition, “Parkinson Disease”
5. National Institute of Neurological Disorders and Stroke, “Parkinson’s Disease”
6. Cleveland Clinic, “Deep Brain Stimulation”
7. American Parkinson Disease Association, “Focused Ultrasound for Parkinson’s Disease”
8. Parkinson’s Foundation, “Treatment”